Pharsight

Sunosi generic

Sunosi is an anti-sleep disorder drug owned by Axsome Malta. It contains the active ingredient solriamfetol hydrochloride and was first authorized for market use on 17th June, 2019. There are a total of 9 patents held for this drug, none of which have expired yet.

When will Sunosi generic be available?

The generic version of Sunosi is expected to be available after 30th December, 2042. This date is determined by the expiration of the patent US11793776, the last active patent held for the drug. The earliest date a drug patent challenge can be filed against Sunosi is 18th June, 2023.

Sunosi uses

Sunosi is primarily used for the treatment of excessive daytime sleepiness. Its effectiveness stems from its active ingredient, Solriamfetol, which can be administered to subjects with varying degrees of renal impairment. Other uses of Sunosi include treating excessive daytime sleepiness in lactating women while limiting infant exposure to the drug and improving wakefulness in adult patients with excessive sleepiness associated with narcolepsy or obstructive sleep apnea (OSA).

Sunosi patent expiration

Sunosi holds 9 patents, the last of which (US11793776) expires on 30th December, 2042, marking the potential release date for Sunosi generics. The earliest a patent challenge can be filed against the drug is 18th June, 2023. Below are the details of the patents:

Sunosi dosage

Want to ask something?